Peptide Epitope Assays for Predicting Cow's Milk Allergy Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing food allergies, particularly cow's milk allergy (CMA), are inadequate in distinguishing different phenotypes and predicting whether pediatric patients will outgrow the allergy, and existing high-throughput assays are costly, labor-intensive, and have reproducibility issues.
Innovation Solution
The use of specific allergenic and non-reactive epitope-containing peptides from cow's milk proteins, conjugated to solid supports, for diagnosing CMA, monitoring clinical tolerance development, and detecting changes in allergic response intensity through methods like microarray, microtiter plate, and flow cytometry assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If microarray-based epitope mapping is used, then measurement precision and information content are improved, but productivity and ease of operation deteriorate due to low throughput and requirement for multiple replicates
Solution Approach 1:
The patent replaces the mechanical microarray spotting and reading system with a bead-based suspension array system that uses flow cytometry for detection. This substitution enables automated high-throughput processing while maintaining the ability to map multiple epitopes simultaneously, resolving the contradiction between measurement precision and productivity.
Solution Approach 2:
The patent changes the physical state of the assay system from a fixed microarray surface to a suspended bead system that can be dynamically processed through flow cytometry. This parameter change enables rapid automated analysis of numerous peptides in parallel, significantly improving throughput while preserving epitope mapping capability.
2Measurement precision
If spot membrane-based immunoassays are used, then epitope mapping capability is improved, but device complexity and ease of manufacture worsen due to requiring large numbers of peptides and labor-intensive procedures
Solution Approach 1:
The patent creates a universal bead-based platform where a single type of bead system can be used to assay multiple different peptides through simple mixing and flow cytometry detection. This universal approach eliminates the need for complex membrane-based procedures and large numbers of individually prepared spots, reducing device complexity while maintaining multi-epitope mapping capability.
Solution Approach 2:
The patent combines multiple peptide assays into a single reaction volume by suspending differently coded beads with their respective peptides together with patient serum. This merging of multiple individual assays into one combined assay dramatically simplifies the procedure and reduces the number of steps required, addressing the complexity issue.
3Ease of operation
If conventional IgE testing is used, then ease of operation is improved, but measurement precision and information content worsen due to weak correlation with clinical sensitivity and inability to distinguish phenotypes
Solution Approach 1:
The patent segments the overall IgE response into multiple discrete epitope-specific measurements by testing against numerous different peptide sequences. This segmentation provides detailed information about which specific epitopes are recognized, improving measurement precision and enabling phenotype differentiation while maintaining operational simplicity through automated bead-based assays.
Solution Approach 2:
The patent introduces peptide epitopes as intermediaries between the patient's IgE antibodies and the detection system. By measuring IgE binding to specific peptide epitopes rather than whole allergens, the assay achieves better correlation with clinical sensitivity and provides more precise diagnostic information while keeping the procedure simple through standardized bead-based protocols.
4Productivity
If bead-based multiplexing is used, then productivity and sample volume efficiency are improved, but manufacturing cost and device complexity increase due to requiring specialized detection instruments
Solution Approach 1:
The patent replaces complex specialized bead reading instruments with standard flow cytometry equipment that is more widely available and easier to operate. The flow cytometry system automatically detects the fluorescent codes on beads and quantifies peptide-specific IgE binding, maintaining high productivity while reducing device complexity and improving accessibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides accurate diagnosis of CMA, predicts clinical tolerance, and monitors changes in allergic response intensity with high-throughput, reduced sample volume, and lower cost, using peptide-based assays.
Implementation Method 1
contacting each solid support with serum obtained from the subject under conditions sufficient to permit binding of allergy-associated immunoglobulin (AAI) in the serum to the peptide on each solid support to form a peptide-AAI complex
Implementation Method 2
The beads are analyzed by flow cytometry
Implementation Method 3
An AAI-specific labeling reagent comprising a fluorescent reporter moiety is then bound to the AAI of the complex
Data Source
AI summary
Provided are peptide biomarkers for diagnosis of allergy, monitoring development of clinical tolerance in an allergic individual, and predicting whether an allergic subject is likely to develop clinical or natural tolerance over time. The invention also relates to diagnostic methods and diagnostic kits employing the peptide biomarkers.